Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
341 Leser
Artikel bewerten:
(2)

Dundon Advisers LLC: Endo GUC Trust Announces Initial Distribution of Class A Units and Cash

Finanznachrichten News

WHITE PLAINS, NY / ACCESSWIRE / October 30, 2024 / Matthew Dundon, acting in his capacity as the GUC Trustee of the Endo GUC Trust (the "Trust") announced today that it has commenced a distribution of Class A Units of beneficial interests in the Trust and cash to those former holders of second lien and unsecured notes (the "Notes") issued by Endo International plc and certain of its affiliates (the "Debtors") who have timely tendered their escrow positions and complied with all other requirements to receive the Class A Units pursuant to the chapter 11 plan (the "Plan") confirmed in the bankruptcy cases of the Debtors and the Endo GUC Trust Agreement (the "Trust Agreement").

A maximum of 170 million Class A Units are issuable by the Trust. Class A-1 Units are issuable to former holders of Notes who timely certified that they are qualified institution buyers, and Class A-2 Units are issuable to former holders of Notes who timely certified that they are accredited institutional investors, as those investor statuses are defined in the Trust Agreement. Former holders of Notes who certified that they are neither qualified institutional buyers nor accredited institutional investors are eligible to receive Class A-3 Units. All Class A Units entitle their holders to the same distributions of cash from the Trust on a per unit basis. The initial distribution of cash to holders of Class A Units is approximately $0.1370588 per unit, for a total distribution of approximately $23.3 million, less amounts deducted for unclaimed distributions.

The following table provides information regarding the issuance of the Class A Units and related cash distribution:

Series of Notes

Pre-Unit Issuance

Contra CUSIP

Unit Issuance Rate per $1,00 of Principal Amount

Rate of Initial Cash Distribution per $1,000 Principal Amount

9.5% Second Lien Notes due 2027

29299BAG9

76.2607884

$10.45

29299BAH7

29299BAJ3

5.375% Senior Unsecured Notes due 2023

29299BAK0

72.8460022

$9.98

29299BAL8

29299BAM6

6.0% Senior Unsecured Notes due 2028

29299AZW9

73.0663029

$10.01

29299AZX7

29299AZY5

6.0% Senior Unsecured Notes due 2023

29299AZZ2

72.8964473

$9.99

29299BAB0

29299BAC8

6.0% Senior Unsecured Notes due 2025

29299BAD6

74.38733222

$10.20

29299BAE4

29299BAF1

Distributions of the Class A-1 Units and the Class A-2 Units and the initial cash distribution thereon were made beginning on October 25, 2024 through customary Depository Trust Company ("DTC") procedures. The CUSIP number for the Class A-1 Units is 29281F105 and the CUSIP number for the Class A-2 Units is 29281F113.

The Class A-3 Units represent the right to receive distributions from the Trust, are non-transferrable and do not constitute securities. Class A-3 Units will be reflected on a register maintained by Equiniti Trust Company, LLC, the Trust's transfer agent. Cash distributions on the Class A-3 Units will be made by Stretto, Inc., the Trust's distribution agent, by wire transfer in accordance with the banking information provided by the holders to the Trust.

As the Class A-1 Units and Class A-2 Units are subject to significant transfer restrictions, the Trust suggests any person who desires to transfer or receive by transfer any Class A-1 Units and Class A-2 Units consult with qualified advisers concerning compliance with such restrictions. As noted, the Class A-3 Units are non-transferable.

Further information regarding the Trust and documents related to the Class A Units, including the Plan and the Trust Agreement, can be found at www.EndoGUCTrust.com .

###

Contact: Joshua Nahas, jn@dundon.com , (914) 341-1188.

SOURCE: Dundon Advisers LLC



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.